No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

MindPortal Raises $5 Million

Editor: What To Know

  • Namely, a portable and non-invasive platform that samples brain activity at high spatial and temporal resolution, a technical feat that could unleash the potential for a dramatic improvement in productivity across work, play and life.
  • “All technology has been generated from the ingenuity of the human mind, but for the first time in the history of our species, we are turning that ingenuity towards creating technology that enhances the human mind itself,”.
  • “We’re animated by a vision of the future where every human on the planet has a greater opportunity to fully develop their talents and minds,”.

MindPortal creators of the next personal computer that is a wearable non-invasive brain-computer interface, announced today it completed a $5 Million seed round of financing.

Learn Capital led the round, with additional investment from Kleiner Perkins; Dan Siroker, Founder & CEO of Scribe AI; Matt Bellamy, rockstar and frontman of Muse; James Park, Co-Founder & CEO of Fitbit; Julie Zhou, Co-Founder of Sundial and former Vice President of Product Design for Facebook; Scrum Ventures; and additional angels from frontier tech, hardware and product design. Previous pre-seed investors included 7pc and Y Combinator. The new funding will be used to hire additional neuroscientists, product engineers and machine learning experts.

Presently, MindPortal’s patent pending wearable device can record human brain activity in real time, without surgery, with 10-100x more precision than EEG technology. The platform brain computer being developed will act as a bi-directional portal; connecting the mind to immersive, creative and playful experiences and also as a gateway into the mind. When wearing MindPortal’s device, people will be able to create and share new experiences e.g. in VR/AR, just by using their thoughts, and channel experiences into their mind.

“We’re animated by a vision of the future where every human on the planet has a greater opportunity to fully develop their talents and minds,” said Rob Hutter, Founder & Managing Partner of Learn Capital. “MindPortal is pursuing what some would call the holy grail – namely, a portable and non-invasive platform that samples brain activity at high spatial and temporal resolution, a technical feat that could unleash the potential for a dramatic improvement in productivity across work, play and life.”

“All technology has been generated from the ingenuity of the human mind, but for the first time in the history of our species, we are turning that ingenuity towards creating technology that enhances the human mind itself,” Ekram Alam, Co-founder & CEO of MindPortal.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy